Navigation Links
Watson Confirms Welchol® Patent Challenge
Date:4/20/2011

PARSIPPANY, N.J., April 20, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colesevelam HCI 625 mg tablets.  Watson's Colesevelam HCI tablets are a generic version of Daiichi Sankyo, Inc.'s Welchol®.

Daiichi Sankyo and Genzyme Corporation filed suit against Watson on April 18, 2011 in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent Nos. 5,607,669 and 5,693,675.  Daiichi Sankyo's lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until September 25, 2013, or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.  

For the twelve months ending February 2010, Welchol® tablets had total U.S. sales of approximately $336 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company.  The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release.  It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation; the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

Welchol® is a trademark of Daiichi Sankyo, Inc.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:

Investors:
Patty Eisenhaur
(973) 355-8141

Media:
Charlie Mayr
(973) 355-8483


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
2. Watson to Host Conference Call and Webcast to Discuss First Quarter 2011 Earnings
3. Watson Announces Approval of Nulecit™, the First Generic Alternative to Ferrlecit® for the Treatment of Iron Deficiency Anemia
4. Watson Confirms Favorable Appeals Court Ruling on Generic SEASONIQUE® Patent Challenge
5. Watson Confirms OxyContin® Patent Challenge
6. Watson Confirms District Court Ruling in Generic Fentora® Patent Suit
7. Cephalon Wins FENTORA Patent Suit Against Watson
8. Watson Launches Generic Famvir®
9. Heygood, Orr & Pearson: Los Angeles Court Orders Watson Pharmaceuticals to Produce Documents, Provide Depositions in Fentanyl Patch Death Lawsuit
10. Watson Announces Favorable District Court Ruling in Generic Fentora® Patent Suit
11. Watson Promotes David Buchen, R. Todd Joyce to Executive Vice President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Aug. 15, 2017   Mostyn Law and Gulf Coast ... Houston, Texas . The Mostyn Law family has ... years. That is why Mostyn Law is partnering with ... to show its appreciation. Blood supplies are running low. ... short of hospital needs in August. That is why the blood ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017  Axium Pharmaceuticals Inc., the creator ... rumored to be in the beginning stages of an IPO. ... on epilepsy medications with the average cost of a prescription epilepsy drug ... ... Another staggering figure is the fact ...
(Date:8/15/2017)... , Aug. 15, 2017  AOTI Inc. announced today that its ... Inc., has recently opened a New York City Office in ... of its unique Topical Wound Oxygen (TWO 2 ) homecare therapy. ... Accreditation Commission for Health Care (ACHC) under the company,s DMEPOS accreditation ... ...
Breaking Medicine Technology:
(Date:8/19/2017)... ... August 19, 2017 , ... Praeclarus Press ... mothers. These illustrations show the diversity of the breastfeeding mothers, using bright ... range of sizes. These illustrations are also available on tote bags, notepads, smartphone ...
(Date:8/18/2017)... ... August 19, 2017 , ... Mr. Noppadon Pakprot, Deputy ... Amazing Thailand Health and Wellness Tourism Showcase 2017 yesterday, which unveiled the latest ... for Tourism Products and Business at TAT said, “Thailand has long been recognized ...
(Date:8/18/2017)... ... August 18, 2017 , ... August ... “Vision & Hearing,” advocating for active, healthy lifestyles and highlighting the importance of ... individuals with hearing impairments and shares the latest innovations in hearing aid technology. ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... consulting services and asset protection assistance to communities in North-Central West Virginia, is ... critical services to at-risk boys in the area. , The Chestnut Mountain Ranch ...
(Date:8/18/2017)... ... 2017 , ... The Golseth Agency, a Texas based insurance management and financial ... regional charity campaign organized to provide support to Christina Upchurch and her two children ... and her children returned from out of town to find her husband passed away ...
Breaking Medicine News(10 mins):